Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acalabrutinib for Chronic Graft-Versus-Host Disease

NCT04198922 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT04198922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04198922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acalabrutinib for Chronic Graft-Versus-Host Disease
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 11, 2020
Completion date
April 30, 2027
Enrollment
51 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, recurrent moderate-severe chronic graft versus host disease